Transaortic valve replacement, complications and validation of a protocol in ICU
© Berrazueta et al.; 2015
Published: 1 October 2015
Aortic stenosis(AS) is the most prevalent valvular disease (incidence 2% over 65years). Valvular area decreases 0.3m/s/y, transvalvular gradient (7mmHg/y) and blood speed(0.3m/s/y) increases with age. AS treatment can be medical or surgical:heart valve replacement surgery or percutaneous placement of an aortic endoprothesis(TAVR) in patients with high perioperative risk.TAVR is beneficial and improves their expectative and quality of life (QOL) compared with medical treatment.
To describe the incidence of complications of TAVR and to determine the validity of our protocol.
Descriptive observational study during 2012-2014 of TAVR complications with Corevalve device at Burgos University Hospital.We analyzed epidemiological characteristics, comorbidities, and complications.We applied the actual protocol in all patients, which consist in femoral artery access, provisional pacemaker(PM), antibiotic and high digestive bleeding prophylaxis.During TAVR patients are superficially sedated and ventilated with self-expanded balloon. Afterwards patients are admitted to ICU continuing hemodynamic monitoring, neurologic vigilance, and vascular access care hourly. Systematically and detailed echocardiography is made.Double antiaggregation and haemoglobin are optimized. Seriated blood tests are taken. If there is no atrioventricular block(AVB) after 24 hours the PM is removed.
Acute Kidney Injury(AKI)
Complications after TAVR implantation.
Residual Aortic Regurgitation
Valvular migration and prosthesis recolocation
2.7 (SD 0.3)
11.23 (SD 1.36)
30 days Mortality
1 year Mortality
TAVR using our protocol is a safe technique but not free of complications in patients with high surgical risk. Most of these complications were transfusion requirements, conduction system abnormalities, and AKI resolved at discharge. No nosocomial infections or need of prolonged mechanical ventilation was observed. These results are comparable to the experience in other centers, so we validate our protocol.
- Data I, Burzotta F, Trani C, Crea F, Ussia GP: Percutaneous management of vascular access in transfemoral transcatheter aortic valve implantation. World J Cardiol. 2014, 6 (8): 836-846. 10.4330/wjc.v6.i8.836.View ArticleGoogle Scholar
- Toggeweiler S, Leipsic J, Binder RK, Freeman M, Barbanti M, Heijmen RH, et al: Management of Vascular Access in Transcatheter Aortic Valve Replacement. Part 2:Vascular Complications. JACC Cardiovasc Interv. 2013, 6 (8): 767-776. 10.1016/j.jcin.2013.05.004.View ArticleGoogle Scholar
- Stahli BE, Maier W, Corti R, Luscher TF, Jenni R, Tanner FC: Aortic regurgitation after transcatheter aortic valve implantation: mechanisms and implications. Cardiovasc Diagn Ther. 2013, 3 (1): 15-22.PubMedPubMed CentralGoogle Scholar
- Piazza N, Lange R, Martucci G, Serruys PW: Patient selection for transcatheter aortic valve implantation: Patient risk profile and anatomical selection criteria. Arch Cardiovasc Dis. 2012, 105 (3): 165-173. 10.1016/j.acvd.2012.02.007.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.